Akari Therapeutics Plc Stock Performance
as on November 1, 2025 at 1:29 am IST
Day's Low
Day's High
$0.7$0.76
5.41%
Downside
2.70%
Upside
52 Week's Low
52 Week's High
$0.57$2.9122.78%
Downside
293.24%
Upside
Akari Therapeutics Plc share price movements today
- Previous Close
- $0.73
- Open
- $0.72
- Volume
- 541.3K
- Day's Low - High
- $0.7 - $0.76
- 52 Week Low - High
- $0.57 - $2.91
Akari Therapeutics Plc Historical Returns
- 1 Month Return
- -18.12 %
- 3 Month Return
- -25.74 %
- 1 Year Return
- -73.02 %
- 3 Year Return
- -92.35 %
- 5 Year Return
- -97.56 %
Akari Therapeutics Plc Stock Fundamentals & Key Indicators
Check Akari Therapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$24.5M
EPS (TTM)
-0.45
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-12.8M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-112.02%
Akari Therapeutics Plc vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Akari Therapeutics Plc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $24.5M | -97.56% | NA | 0.00% | |
| BUY | $40.4B | 478.23% | -16.34 | -264.83% | |
| BUY | $60.2B | 253.38% | 1425.12 | 1.36% | |
| BUY | $109.1B | 101.56% | 30.31 | 31.86% | |
| BUY | $68.5B | 16.98% | 15.62 | 32.13% |
Stock Returns calculator for Akari Therapeutics Plc Stock including INR - Dollar returns
The Akari Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Akari Therapeutics Plc investment value today
Current value as on today
₹32,325
Returns
Returns from Akari Therapeutics Plc Stock
Dollar Returns*
₹5,706 (+5.71%)
Analyst Recommendation on Akari Therapeutics Plc Stock
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Akari Therapeutics Plc. Average target price of $4.53
Akari Therapeutics Plc Share Price Target
Get share price movements and forecasts by analysts on Akari Therapeutics Plc.
What analysts predicted
83.66%UPSIDE
Target Price
$4.53
Current Price
$0.74
Analyzed by
7 Analysts
Target
$4.53
Akari Therapeutics Plc target price $4.53, a slight upside of 83.66% compared to current price of $0.74. According to 7 analysts rating.
Akari Therapeutics Plc Quarterly Profit & Loss
All numbers in Millions USD
Akari Therapeutics Plc Annual Profit & Loss
All numbers in Millions USD
Akari Therapeutics Plc Quarterly Cash Flow
All numbers in Millions USD
Akari Therapeutics Plc Annual Cash Flow
All numbers in Millions USD
Insights on Akari Therapeutics Plc
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
NO EFFECTAgainst Peers
In the last 3 years, Insmed Incorporated has given 1009.8% return, outperforming this stock by 1102.0%
- NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 184.3% return, outperforming this stock by 258.0%
NEGATIVE IMPACTPrice Dip
In the last 1 month, AKTX stock has moved down by -25.5%
About Akari Therapeutics Plc
| Organisation | Akari Therapeutics Plc |
| Headquarters | 22 Boston Wharf Road, Boston, MA, United States, 02210 |
| Industry | Health Technology |
| CEO | Mr. Abizer Gaslightwala |
| E-voting on shares | Click here to vote |
Key Management of Akari Therapeutics Plc
Name | Title |
|---|---|
Dr. Satyajit Mitra Ph.D. | Executive Director & Head of Oncology |
Mr. Mark F. Kubik M.B.A. | Head of Business Development - Oncology |
Mr. Abizer Gaslightwala | CEO, President & Director |
Dr. Torsten Hombeck Ph.D. | Consultant |
FAQs
What is Akari Therapeutics Plc share price today?
Akari Therapeutics Plc share price today is $0.74 as on at the close of the market. Akari Therapeutics Plc share today touched a day high of $0.76 and a low of $0.7.
What is the 52 week high and 52 week low for Akari Therapeutics Plc share?
Akari Therapeutics Plc share touched a 52 week high of $2.91 on and a 52 week low of $0.57 on . Akari Therapeutics Plc stock price today i.e. is closed at $0.74,which is 74.57% down from its 52 week high and 29.51% up from its 52 week low.
What is Akari Therapeutics Plc's market capitalisation today?
Akari Therapeutics Plc market capitalisation is $0.00T as on .
How to invest in Akari Therapeutics Plc Stock (AKTX) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Akari Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Akari Therapeutics Plc Shares that will get you 2.0270 shares as per Akari Therapeutics Plc share price of $0.74 per share as on November 1, 2025 at 1:29 am IST.
What is the minimum amount required to buy Akari Therapeutics Plc Stock (AKTX) from India?
Indian investors can start investing in Akari Therapeutics Plc (AKTX) shares with as little as ₹88.719 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.19 in Akari Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Akari Therapeutics Plc share’s latest price of $0.74 as on November 1, 2025 at 1:29 am IST, you will get 13.5135 shares of Akari Therapeutics Plc. Learn more about
fractional shares .
What are the returns that Akari Therapeutics Plc has given to Indian investors in the last 5 years?
Akari Therapeutics Plc stock has given -97.56% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?